Sofosbuvir / Velpatasvir

Rosuvastatin

Dosage adjustment may be necessary.

Available pharmaceutical opinion

Document made available to the pharmacist to communicate a drug interaction to the doctor.

DOWNLOAD
Mechanism

Sofosbuvir / Velpatasvir may inhibit hepatic transports OATP1B1/B3 and BCRP and increase plasma concentration of Rosuvastatin.

Sofosbuvir / Velpatasvir

Pharmacodynamic effects

Recommendations

Alternative solution(s)

Rosuvastatin

Pharmacodynamic effects

Possible increased risk of HMG CoA inhibitor toxicity.

Recommendations

Start with a small dosage. Monitor closely for signs and symptoms of toxicity and adjust dosage as a function of efficacy and tolerance.

We do not recommend more than 10 mg per day.

Alternative solution(s)

Monitor

Symptoms of toxicity associated with hypolipidemic agents : gastrointestinal effects, fatigue and muscular weaknesses, myalgias, muscular cramps, myopathies, rhabdomyolysis and myoglobinuria leading to renal insufficiency.

Tests

CK

ALT

AST

Lipidic profile

Pharmacokinetic parameters
Parameters
Reference number
# patients
HCV
Dose
Frequency
AUC
Cmax
Sofosbuvir / Velpatasvir
3250
18
-
100 mg *
QD
 
 
Rosuvastatin
3250
18
-
20 mg
x 1
+ 169% (2.7x)
+ 161% (2.6x)
Comment

Ref #3250 : * This study was conducted with velpatasvir alone but no significant interaction is anticipated with sofosbuvir. The effects on velpatasvir have not been studied but no significant change is anticipated.

Reference
  • 3250
    Sofosbuvir/Velpatasvir (Epclusa), Gilead Sciences, Ontario, Canada, 16 avril 2018.